Abstracts Archive - Page 564 of 2425 - ACR Meeting Abstracts

Abstract Number: 0176 • ACR Convergence 2021
Semi-quantitative Chest Computed Tomography (CT) Analysis in Pediatric Rheumatologic (PR) Patients with Diffuse Lung Disease
Michal Cidon¹, Terry Robinson², Beverley Newman³, Paul Iskander², Paul Thacker⁴, Evan Zucker³, Brian Bartholmai⁴, Dnyanesh Tipre², Tzielan Lee⁵, Rajdeep Pooni⁶ and Rex Moats², ¹Children's Hospital Los Angeles, Los Angeles, CA, ²Children's Hospital of Los Angeles, Los Angeles, CA, ³Stanford Children's Health, Stanford, ⁴Mayo Clinic, Rochester, MN, ⁵Stanford University School of Medicine, Palo Alto, CA, ⁶Stanford Children's Health, Palo Alto, CA
Background/Purpose: Spiral chest CT (SCT) is commonly used to evaluate subclinical lung disease in pediatric rheumatology. However, there are no validated scoring tools to objectively…
Abstract Number: 0179 • ACR Convergence 2021
Impaired Myocardial Flow Reserve on 82Rubidium Positron Emission Tomography Imaging Predicts Adverse Events in Patients with Autoimmune Rheumatic Disease
Attila Feher¹, Nabil Boutagy¹, Evangelos Oikonomou¹, Yi-Hwa Liu¹, Edward Miller¹, Albert Sinusas¹ and Monique Hinchcliff², ¹Yale School of Medicine, New Haven, CT, ²Yale School of Medicine, Westport, CT
Background/Purpose: Coronary microvascular dysfunction (CMVD) has been described in patients with autoimmune rheumatic disease (ARD). By noninvasive evaluation of myocardial blood flow (MBF) and myocardial…
Abstract Number: 0178 • ACR Convergence 2021
Abdominal Obesity May Confound Accuracy of Cardiovascular Risk Prediction in Rheumatoid Arthritis; Can Coronary Atherosclerosis Imaging and Biomarkers Help?
George Karpouzas¹, sarah ormseth², Elizabeth Hernandez² and Matthew Budoff³, ¹Harbor-UCLA Medical Center, Torrance, CA, ²The Lundquist Institute, Harbor-UCLA Medical Center, Torrance, CA, ³Division of Cardiology, and the Lundquist Institute ay Harbor-UCLA Medical Center, Torrance, CA
Background/Purpose: Accurate cardiovascular risk stratification is essential in rheumatoid arthritis (RA) care. Previous studies evaluated the impact of obesity (defined as body mass index) on…
Abstract Number: 0177 • ACR Convergence 2021
Dual-Energy Computed Tomography Three Material Decomposition Improves the Sensitivity of Gout Detection
Justin Tse¹, Douglas Kondro², Yves Pauchard³, Andrea Veljkovic⁴, Viviane Frasson⁵, David Holdsworth⁶, Sarah Manske⁷, Paul MacMullan⁸ and Peter Salat⁷, ¹UNIVERSITY OF CALGARY, Calgary, AB, Canada, ²STEMCELL Technologies, Cambridge, United Kingdom, ³Department of Electrical and Software Engineering, Schulich School of Engineering, Calgary, AB, Canada, ⁴University of British Columbia, Department of Orthopaedics, Vancouver, BC, Canada, ⁵University of Calgary, Human Performance Lab, Calgary, AB, Canada, ⁶University of Western Ontario, Department of Surgery, London, ON, Canada, ⁷University of Calgary, Department of Radiology, Calgary, AB, Canada, ⁸University of Calgary, Department of Rheumatology, Calgary, AB, Canada
Background/Purpose: Gout, a curable musculoskeletal disease, is characterized by the deposition and accumulation of monosodium urate (MSU) crystals within affected joints. Dual-energy computed tomography (DECT),…
Abstract Number: 0172 • ACR Convergence 2021
Assessing Relevant Joints for Monitoring CPPD Diseases: A Systematic Literature Review of Imaging Techniques by the OMERACT Ultrasound – CPPD Subgroup
Antonella Adinolfi¹, Silvia Sirotti², Garifallia Sakellariou³, Edoardo Cipolletta⁴, Emilio Filippucci⁵, Francesco Porta⁶, Piercarlo Sarzi-Puttini⁷, Carlo Alberto Scire⁸, Helen Keen⁹, Peter Mandl¹⁰, Carlos Pineda¹¹, Lene Terslev¹², Maria Antonietta D'Agostino¹³, Nemanja Damjanov¹⁴, Annamaria Iagnocco¹⁵ and Georgios Filippou¹⁶, ¹Rheumatology Unit, Grande Ospedale Metropolitano Niguarda, Milan, Italy, ²Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Milan, Italy, ³Division of Rheumatology, IRCCS Policlinico San Matteo Foundation, University of Pavia, Pavia, Italy, ⁴Rheumatology Unit, Department of Clinical and Molecular Sciences, Università Politecnica delle Marche, Ancona, Italy, ⁵Rheumatology Unit, Department of Clinical and Molecular Sciences, Università Politecnica delle Marche, Jesi, Italy, ⁶INS, Institute of Neurosciences, Florence, Italy, ⁷L.Sacco University Hospital, Milano, Italy, ⁸SIR Epidemiology, Research Unit, Pavia, Italy, ⁹University of Western Australia, Daglish, Australia, ¹⁰Medical University of Vienna, Vienna, Austria, ¹¹Instituto Nacional de Rehabilitacion, Mexico City, Federal District, Mexico, ¹²Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen University, Glostrup, Denmark, ¹³Rheumatology, Fondazione Policlinico Universitario “Gemelli”, IRCCS, Rome, Italy, ¹⁴University of Belgrade School of Medicine, Institute of Rheumatology, Belgrade, Serbia, ¹⁵University of Turin, Roma, Italy, ¹⁶Rheumatology Department, Luigi Sacco University Hospital, Siena, Italy
Background/Purpose: Imaging has been extensively used for the diagnosis of Calcium Pyrophosphate Deposition Disease (CPPD) but the exact prevalence of joint calcifications at imaging in…
Abstract Number: 0183 • ACR Convergence 2021
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 24-Week Results from the Phase 3, Randomized, Double-blind Clinical Trial for CsDMARD-IR and Bio-IR Patients
Merav Lidar¹, Jacob Aelion², Gareth Scott Tarr³, Kim Papp⁴, Lisa Barcomb⁵, Ahmed M. Soliman⁵, Wenjing Lu⁶, Ann Eldred⁵ and Andrew Ostor⁷, ¹Chaim Sheba Medical Center, Ramat Gan, Israel, ²Arthritis Clinic and West Tennessee Research Institute, Jackson, TN, ³Winelands Medical Research Centre and the Institute of Orthopaedics and Rheumatology (IOR), Winelands Medi-Clinic Orthopaedic Hospital, Stellenbosch, South Africa, ⁴K Papp Clinical Research and Probity Medical Research, Waterloo, ON, Canada, ⁵Abbvie Inc., North Chicago, IL, ⁶AbbVie Inc., North Chicago, ⁷Monash University, Cabrini Hospital, and Emertius Research, Malvern, Australia
Background/Purpose: Risankizumab (RZB) is a humanized immunoglobulin G1 monoclonal antibody that specifically inhibits interleukin 23 by binding to its p19 subunit. RZB is being investigated…
Abstract Number: 0182 • ACR Convergence 2021
Tenderness and Radiographic Progression in Rheumatoid Arthritis and Psoriatic Arthritis
Irina Gessl¹, Mihaela Popescu², Gabriela Supp¹, Martina Durechova¹, Michael Zauner¹, Josef Smolen¹, Daniel Aletaha³ and Peter Mandl¹, ¹Medical University of Vienna, Vienna, Austria, ²Maisonneuve Rosemont Hospital, Longueuil, QC, Canada, ³Medical University Vienna, Vienna, Austria
Background/Purpose: In rheumatoid arthritis (RA) and psoriatic arthritis (PsA), swelling is regarded as a sign of synovitis and is associated with radiographic progression. However, recent…
Abstract Number: 0180 • ACR Convergence 2021
Impaired Myocardial Flow Reserve on 82Rubidium Positron Emission Computed Tomography in Patients with Systemic Sclerosis
Attila Feher¹, Nabil Boutagy¹, Evangelos Oikonomou¹, Stephanie Thorn¹, Yi-Hwa Liu¹, Edward Miller¹, Albert Sinusas¹ and Monique Hinchcliff², ¹Yale School of Medicine, New Haven, CT, ²Yale School of Medicine, Westport, CT
Background/Purpose: To investigate the association between Raynaud phenomenon (RP) and coronary microvascular dysfunction, we measured myocardial flow reserve (MFR) using positron emission tomography/computed tomography (PET/CT)…
Abstract Number: 0184 • ACR Convergence 2021
Phase III, Randomized Trial Comparing Clinical Outcomes Between Patients with Moderate-to-severe Chronic Plaque Psoriasis Receiving Adalimumab Reference Product (RP) Continuously versus Those Who Switched Between BI 695501 and Adalimumab RP
Alan Menter¹, Dorothy McCabe², Benjamin Lang³, Jennifer Schaible⁴ and Sravan Kumar Eduru⁵, ¹Baylor Scott & White, Dallas, TX, ²Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, ³Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany, ⁴Boehringer Ingelheim Pharma GmbH & Co. KG, Boberach, Germany, ⁵(Formerly at) Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany
Background/Purpose: BI 695501 is a FDA-approved biosimilar to adalimumab RP (AbbVie), and is approved in seven indications, including rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis,…
Abstract Number: 0186 • ACR Convergence 2021
Continued Treatment with Nintedanib in Patients with Progressive Fibrosing Autoimmune Disease-Related Interstitial Lung Diseases: Data from INBUILD-ON
Eric Matteson¹, Danielle Antin-Ozerkis², Francesco Bonella³, Nazia Chaudhuri⁴, Vincent Cottin⁵, Heiko Mueller⁶, Carl Coeck⁷, Klaus B Rohr⁸ and Wim A Wuyts⁹, ¹Mayo Clinic College of Medicine and Science, Rochester, MN, ²Section of Pulmonary, Critical Care and Sleep Medicine, Yale University School of Medicine, New Haven, CT, ³Center for Interstitial and Rare Lung Diseases, Pneumology Department, Ruhrlandklinik, University of Duisburg-Essen, Essen, Germany, ⁴North West Interstitial Lung Disease Unit, Manchester University Foundation Trust, Wythenshawe, Manchester, UK, Manchester, United Kingdom, ⁵Coordinating Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, University of Lyon, INRAE, Lyon, France, Lyon, France, ⁶Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany, ⁷SCS Boehringer Ingelheim Comm.V., Brussels, Belgium, Brussels, Belgium, ⁸Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim, Germany, ⁹Unit for Interstitial Lung Diseases, Department of Pulmonary Medicine, University Hospitals Leuven, Leuven, Belgium, Leuven, Belgium
Background/Purpose: In the INBUILD trial in patients with progressive fibrosing ILDs other than idiopathic pulmonary fibrosis (IPF), nintedanib reduced the rate of decline in forced…
Abstract Number: 0185 • ACR Convergence 2021
Phase 1 Study Results of GS-5718, an Oral IRAK4-Inhibitor: Pharmacodynamics of Single and Multiple Doses of GS-5718 in Healthy Subjects
Silke Roedder¹, Emily Wendt², Chad Burris², Jonathan Nazareon², Grace Park³, Phil Pangilinan², Gianna Huang², Anubhav Mathur², James Taylor², Andrew Billin² and Franziska Matzkies⁴, ¹Gilead Sciences, Menlo Park, CA, ²Gilead Sciences, Foster City, CA, ³Gilead Sciences, Seattle, WA, ⁴Gilead Sciences, Inc., Foster City, CA
Background/Purpose: Adaptive and innate immune pathways are involved in inflammation and pathogenesis of autoimmune diseases including Rheumatoid Arthritis (RA) and Lupus Erythematosus (LE). Immune complexes…
Abstract Number: 0181 • ACR Convergence 2021
Magnetic Resonance Imaging Findings in Early Rheumatoid Arthritis: Are There Differences Based on Autoantibody Status?
Caitrin Coffey¹, Gavin McKenzie¹, Nicholas Rhodes¹, Cassondra Hulshizer¹, Cynthia Crowson², John Davis¹ and Kerry Wright¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Eyota, MN
Background/Purpose: Magnetic resonance imaging (MRI) is increasingly used as an adjunct to the physical examination in early rheumatoid arthritis (RA). Characteristic differences in MRI findings…
Abstract Number: 0175 • ACR Convergence 2021
Correlation of Subclinical Synovitis with Juvenile Idiopathic Arthritis Outcome Measurements
Patricia Vega-Fernandez¹, Edward Oberle², Michael Henrickson¹, Jennifer Huggins¹, Mekibib Altaye³, Amy Cassedy⁴, Johannes Roth⁵ and Tracy Ting¹, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Nationwide Children's Hospital, Columbus, OH, ³Cincinnati Children's Hospital, Cincinnati, OH, ⁴Cincinnati Children's Hospital and Medical Center, Cincinnati, OH, ⁵University of Ottawa, Ottawa, ON, Canada
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is the most common rheumatologic disease of childhood. Active joint count (AJC) is one of the key JIA Core Set…
Abstract Number: 0156 • ACR Convergence 2021
Tenosynovitis Detected by Power Doppler Ultrasound: A Differential Feature of Patients with Seronegative Rheumatoid Arthritis
Einer Sanchez Prado¹, Santiago Ruta², Laura Cuellar¹, Sebastian Magri³ and Rodrigo Garcia Salinas⁴, ¹Hospital Italiano La Plata, La Plata, Argentina, ²Hospital San Martin de La Plata, La Plata, Argentina, ³Hospital Italiano La Plata, La Plata, ⁴Hospital Italiano de La Plata, La Plata, Argentina
Background/Purpose: It is known that seronegative rheumatoid arthritis has different characteristics from seropositive RA. Objectives: To estimate the frequency of rheumatoid arthritis (RA) in a…
Abstract Number: 0127 • ACR Convergence 2021
Interleukin 1 Receptor Antagonist (IL-1Ra) Variable Number of Tandem Repeat (VNTR) Polymorphism in Fibromyalgia Patients in South India
Arun Tiwari¹, Mithun CB², Lalitha Biswas³, Sandeep Surendran³, Vishal Marwaha³, Pranav Chickermane³ and Amisha Shahul³, ¹Amrita Institute of Medical Sciences, Ernakulam, India, ²Amrita Institute of Medical Sciences, Muvattupuzha, India, ³Amrita Institute of Medical Sciences, Kochi, India
Background/Purpose: Interleukin-1 receptor antagonist (IL-1Ra) variable number of tandem repeats (VNTR) polymorphism is a known to influence the production of IL-1Ra and has been considered…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].